

# TABLE OF CONTENTS

April 20, 2009

No. 2136

## BUSINESS

- 1 Leadership Changes at KYORIN
- 2 Kissei's Urief Launched in the US
- 3 Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
- 3 Eli Lilly Licenses Cialis to Nippon Shinyaku
- 3 Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
  - BMS to Outlive Plavix Crunch by Extending Agreement on Abilify
- 4 Pfizer Aims to Become Market Leader for Macrolides with Zithromac SR
- 5 Hisamitsu: Both Sales and Profits Up 8th Year in a Row
  - HFT-290 for Cancer Pain to Be Approved in FY2009

## NEW PRODUCTS

- Merck Serono: Gonalef Subcutaneous Injection Pen

## BUSINESS NEWS IN BRIEF

- SymBio Sublicenses Bendamustine to Cephalon in China
- BioWa Licenses POTELLIGENT Technology to sanofi-aventis
- Eisai Creates Marketing Planning Unit for E7389

## TOPICS

- Shiro Kondo Recognized as Teijin Group Fellow for His Contribution to the Development of Febuxostat

## Commentary

- Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult

## GENERICS

- 8 OHARA to Improve Tablet Distinguishability by ID Printing on Both Sides of Tablet
- 8 **GENERICS NEWS IN BRIEF**
  - Nichi-Iko's Quarterly Sales up 55.9%
  - Taiyo to Conduct Dissolution Tests for All of Its Solid Formulations
  - Daiichi Sankyo Sues 11 More Makers of Cravit Generics
  - Sanofi-aventis Acquires Laboratorios Kendrick in Mexico
- 9 % of Prescriptions Allowing Generic Substitution Down to 52%: Nihon Chouzai
- 9 20% of Hospitals in Shiga Pref. Prohibit Use of Generics as a Rule

## REGULATORY

- 10 CDFS to Review Japan's First Ca Blocker + ARB Combination
- 10 Additional Economic Stimulation Measures Target Unapproved Drugs
- 11 Soaring Medical Expenses Are Mainly due to Drugs: Dr Nakagawa

## REGULATORY NEWS IN BRIEF

- Wyeth Files BLA for Prevnar 13 in US

## R&D

- 12 JPDS to Construct PGx Database for the Japanese
- 12 **R&D NEWS IN BRIEF**
  - Pfizer Stops PIII Sutent Trial in Advanced Breast Cancer
  - BI Completes Treatment of Last Patient in PIII Study of Pradaxa
  - Nobilon Initiates PI Study for Intranasal Influenza Vaccine
  - Seattle Genetics Ties Up with Millennium for ADCs
  - Takara Bio to Supply RetroNectin for Cancer Cell Immunotherapy
  - Erbitux with FOLFIRI More Effective for mCRC: Merck Serono
  - Preclinical Data on Millennium's NAE Inhibitor Published in the *Nature*

## MEDICAL DEVICES

- 14 Asahi Kasei to Globally Develop Business for Evaheart
- 14 Eisai Licenses Out Gliadel Wafer to Nobelpharma
- 14 Agilent Technologies Launch SurePrint G3 Microarray
- 15 Olympus Releases Biliary Stent Jointly with Medinol
- 15 GE, Intel Ally in Home Health Technologies
- 15 Takara Bio Obtains License from Kyoto Univ.
- 16 AMDD Inaugurated with Dr H. Wang as President
  - Appealing Value of Advanced Technology
- 17 **TOPICS**
  - Alpha MOS Sets Up Japanese Subsidiary

## SELF-MEDICATION

- 17 Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
- 17 Council on Regulatory Reform Calls for Continued Permission of Online Sale of OTC Drugs

## MEDICAL FACILITIES & NURSING CARE

- 17 Lifestyle Intervention May Be as Effective as Medication in Japanese with Early Diabetes: DIANA Study
- 18 Some Med Facilities Do Not Apply for KRAS Gene Test as *Senshin-Iryo*
- 18 40 Medical Bills for Zyprexa Rejected due to Problems such as Overdoses
- 19 MIN-IREN Protests against MTPC for Data Falsification
- 19 So-net M3 Survey Shows Physicians Depend on Internet for Information